N-(2-(4-(3-(4-Amino-5-chloro-2-methoxyphenyl)-3-oxopropyl)piperidin-1-yl)ethyl)-3,4-di-methoxybenzenesulfonamide

ID: ALA4760149

Chembl Id: CHEMBL4760149

PubChem CID: 162658420

Max Phase: Preclinical

Molecular Formula: C25H34ClN3O6S

Molecular Weight: 540.08

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(S(=O)(=O)NCCN2CCC(CCC(=O)c3cc(Cl)c(N)cc3OC)CC2)cc1OC

Standard InChI:  InChI=1S/C25H34ClN3O6S/c1-33-23-7-5-18(14-25(23)35-3)36(31,32)28-10-13-29-11-8-17(9-12-29)4-6-22(30)19-15-20(26)21(27)16-24(19)34-2/h5,7,14-17,28H,4,6,8-13,27H2,1-3H3

Standard InChI Key:  PUYALJIWQVIZEV-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4760149

    ---

Associated Targets(Human)

HTR6 Tchem Serotonin 6 (5-HT6) receptor (9749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

HTR4 Serotonin 4 (5-HT4) receptor (2870 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 540.08Molecular Weight (Monoisotopic): 539.1857AlogP: 3.60#Rotatable Bonds: 12
Polar Surface Area: 120.19Molecular Species: NEUTRALHBA: 8HBD: 2
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 10.27CX Basic pKa: 6.93CX LogP: 2.58CX LogD: 2.46
Aromatic Rings: 2Heavy Atoms: 36QED Weighted: 0.31Np Likeness Score: -1.14

References

1. Yahiaoui S,Hamidouche K,Ballandonne C,Davis A,de Oliveira Santos JS,Freret T,Boulouard M,Rochais C,Dallemagne P.  (2016)  Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.,  121  [PMID:27266998] [10.1016/j.ejmech.2016.05.048]

Source